Recent years have seen significant progress in the systemic treatment of hepatocellular
carcinoma (HCC), including the advent of immunotherapy. While several large phase III …

Lung cancer is the second most prevalent cancer and the leading cause of cancer‐related
death worldwide. Surgery, chemotherapy, molecular targeted therapy, immunotherapy, and …

Although kinase inhibitors (KI) frequently portray large interpatient variability, a 'one size fits
all'regimen is still often used. In the meantime, relationships between exposure-response …

Introduction The real-world effectiveness of combination treatment with cytotoxic
chemotherapy and programmed cell death protein-1 or programmed death-ligand 1 inhibitor …

The cost of cancer drugs is a challenge to patients and healthcare systems. Here, we
propose a new paradigm of near-equivalence, which combines various types of evidence to …

A series of novel enantiopure isoxazolidine derivatives were synthesized and evaluated for
their anticancer activities against three human cancer cell lines such as human breast …

Osimertinib is a highly potent and selective third-generation epidermal growth factor
receptor (EGFR) inhibitor, which provides excellent clinical benefits and is now a standard-of …

Resistance to epidermal growth factor receptor (EGFR) inhibitors, from the first-generation
erlotinib to the third generation osimertinib, is a clinical challenge in the treatment of patients …

Osimertinib is a standard of care therapy for previously untreated epidermal growth factor
receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding …

Objective Erlotinib was found to be an effective treatment for metastatic kidney renal cell
carcinoma (KIRC). This study employed bioinformatics to explore the value of erlotinib's …